Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations and analyst consensus. We help you understand fair value estimates and potential upside or downside scenarios for any stock you are considering. Our platform provides multiple valuation methods, comparable company analysis, and discounted cash flow models. Make smarter valuation decisions with our comprehensive tools and expert projections based on Wall Street research.
InflaRx N.V. (IFRX) is a clinical-stage biopharmaceutical company whose shares are currently trading at $1.56 as of April 20, 2026, marking a 1.57% decline in recent trading. This analysis covers key technical support and resistance levels, recent market context for the stock and its sector, and potential price scenarios that traders and investors may monitor in the near term. No recent earnings data is available for the company as of the current date, so recent price action has been driven prim
InflaRx N.V. (IFRX) Stock Mean Reversion (-1.57%) 2026-04-20 - Fundamental Analysis
IFRX - Stock Analysis
4,186 Comments
1,945 Likes
1
Nisan
New Visitor
2 hours ago
Ah, missed the opportunity. 😔
👍 218
Reply
2
Theone
Registered User
5 hours ago
Too late to act… sigh.
👍 226
Reply
3
Boris
Active Reader
1 day ago
Wish I had noticed this earlier.
👍 199
Reply
4
Trayven
Returning User
1 day ago
Missed it… oh well. 😓
👍 127
Reply
5
Ronzell
Engaged Reader
2 days ago
Regret not acting sooner.
👍 285
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.